Skip to content

Ketamine for depression: all studies

Page 106 of 154: studies 1,051 to 1,060 of 1,534, newest first. Back to the ketamine for depression overview

Research

Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression.

Journal of Affective Disorders 2023 Fan Zhang, Chengyu Wang, Xiaofeng Lan et al.

OBJECTIVE Hippocampal functional connectivity (FC) alterations, which may happen following ketamine treatment, play a key role in major depression remission. This study aims to investigate the resting-state FC changes of the hippocampus associated with clinical remission after repeated ketamine infusions. METHODS Forty-four major depressive patients received six intravenous ketamine (0.5 mg/kg)...

The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?

Advances in experimental medicine and biology 2023 Angelos Halaris, John Cook

The glutamatergic system is the primary excitatory pathway within the CNS and is responsible for cognition, memory, learning, emotion, and mood. Because of its significant importance in widespread nervous system function, it is tightly regulated through multiple mechanisms, such as glutamate recycling, microglial interactions, and inflammatory pathways. Imbalance within the glutamatergic system...

Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.

Journal of medical economics 2023 Maryia Zhdanava, Amanda Teeple, Dominic Pilon et al.

To describe real-world esketamine nasal spray access and use as well as healthcare resource use (HRU) and costs among adults with evidence of major depressive disorder (MDD) with suicidal ideation or behavior (MDSI). Adults with ≥1 claim for esketamine nasal spray and evidence of MDSI 12 months before/on the date of esketamine initiation (index date) were selected from Clarivate's Real World...

The use of esketamine in the treatment of patients with oral antidepressant-resistant depression: systematic review and meta-analysis.

Revista da Associacao Medica Brasileira (1992) 2023 Idevaldo Floriano, Antônio Silvinato, Wanderley Marques Bernardo

The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field to standardize how to conduct, and to assist in the reasoning and decision-making of doctors. The information provided by this project must be critically evaluated by the physician responsible for the conduct that will be adopted, depending on the conditions and the...

[Ketamine in antidepressant treatment: a revolution?].

Biologie aujourd'hui 2023 Philippe Fossati

Thirty percent of depressed patients are treatment resistant (TRD) suggesting the need of new therapeutic strategy. Recently, it has been shown that ketamine, an anesthetic agent with dissociative effects, has potent and rapid antidepressant properties. Ketamine is a ionotropic glutamatergic NMDA antagonist that inhibits gabaergic neurons. Its antidepressant effect peaks at 24 h post-treatment....

DOI: 10.1051/jbio/2023023 (opens in new tab) Full text (opens in new tab) Ketamine Algorithme de traitement Dissociation Dépression résistante +5

Neuroinflammation through the vagus nerve-dependent gut-microbiota-brain axis in treatment-resistant depression.

Progress in Brain Research 2023 Kenji Hashimoto

Neuroinflammation plays a key role in the pathogenesis of major depressive disorder (MDD), including treatment-resistant depression (TRD). Patients with TRD have higher levels of inflammatory biomarkers compared with responders to antidepressants. Multiple lines of evidence suggest that the gut-microbiota-brain axis via the vagus nerve plays a key role in neuroinflammation. Preclinical and...

Reductions in anxiety and depression symptoms in a subset of outpatients with problematic substance use who received ketamine-assisted psychotherapy: a two-year retrospective chart review.

Frontiers in Psychiatry 2023 Emily Whinkin, Therry Rose J Eparwa, Michelle C Julseth et al.

Assess changes in symptoms of anxiety, depression, and psychosocial or spiritual distress before and after ketamine-assisted psychotherapy (KAP) in individuals with problematic substance use (PSU). A retrospective chart review was performed on participant data from two five-year prospective outcomes studies: the AIMS Medical Outcomes Study (AMOS) and the AIMS Cancer Outcomes Study (ACOS). The...

Clinical case report: considerable improvement of severe and difficult-to-treat obsessive-compulsive disorder with comorbid depression under treatment with esketamine and concomitant psychotherapy.

Frontiers in Psychiatry 2023 Alexander Kaltenboeck, Elisa Foerster, Sabrina Strafner et al.

A 28-year-old man was admitted to our psychiatric ward with severe obsessive-compulsive disorder (OCD) and comorbid depression. At intake, obsessive-compulsive symptoms were present most time of the day and were related to an intense fear of causing interpersonal misunderstandings. Various treatment attempts, including cognitive-behavioural therapy (CBT) with exposure and response prevention...

DOI: 10.3389/fpsyt.2023.1291077 (opens in new tab) Full text (opens in new tab) Depression Case report Ketamine-assisted psychotherapy Obsessive-compulsive disorder

Virtual Reality as an Adjunct to Ketamine Infusion Therapy Increases Patient Satisfaction in the Management of Chronic Pain and Depression: A Retrospective Pilot Study

Journal of Behavioral and Brain Science 2023 Melissa C. Selinger, David M. Compton, Hamilton Morris et al. 3 citations

The management of patients with concomitant chronic pain (CP) and Major Depressive Disorder (MDD) remains challenging for clinicians. Current chronic pharmacologic management is often unsuccessful, or has intolerable side effects to the patients. While not restricted to patients with chronic pain, these patients are often diagnosed with depression, presenting with symptoms such as poor mood,...

Ketamine as an alternative to ECT in catatonia in elderly women with bipolar disorder: A case report.

Frontiers in Psychiatry 2023 Shanthi Sarma, Arulmathy Arunachalam, Memunatu Kamara et al. 6 citations

The following paper described two cases of patients with catatonic depression in bipolar disorder (BD) referred to our electroconvulsive therapy (ECT) service. Both were deemed not medically fit for ECT, and were, instead, treated with intravenous (IV) ketamine. Both responded with a resolution of symptoms, returning to baseline level of functioning. During the COVID-19 pandemic, given the...